Topics

"NANITE" strategy amplifies genome editing in vivo by turning transfected cells into temporary factories that deliver Cas9 to their neighbors.

Breakthrough uses directed evolution to develop versatile tool for medicine and research, overcoming natural limits of DNA-copying enzymes.

A Boston startup gains FDA approval to begin the first clinical trial using cellular reprogramming to treat eye disease, with potential implications for reversing aspects of aging.

Anthrobots: Where human cells become self-assembling, tissue-repairing biobots. Is this the dawn of cellular medicine’s next frontier?

This advance shows a way to make important immune cells in the lab, potentially creating ready-to-use treatments that are cheaper and more widely available for serious illnesses.

New "TNT" method mimics the reset of a cell’s epigenome that happens in very early embryonic development

In 2025, biotech paired real clinical breakthroughs with harsh commercial reality, forcing the sector to abandon long-term narratives in favour of near-term revenue, scalability, and regulatory survival.

Researchers develop a biodegradable artificial synapse that uses less energy than the human brain, enabling sustainable neuromorphic electronics and temporary intelligent devices.

Scientists have created a mouse using molecular tools derived from our single-celled distant ancestors, which predate animal life.

Artificial genes can construct complex structures inside cells by following a sequence similar to how IKEA furniture is assembled.